Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
This long-term extension study is an open-label, multiple-dose study to evaluate the
long-term safety, tolerability, efficacy and PD of vamorolone administered once daily by
liquid oral suspension over a Treatment Period of 24 months to young boys with DMD who
participated in the VBP15-002 Phase IIa and VBP15-003 Phase IIa extension core studies.
Phase:
Phase 2
Details
Lead Sponsor:
ReveraGen BioPharma, Inc.
Collaborators:
Cooperative International Neuromuscular Research Group University of Pittsburgh